♠ 주제 : NK cell-based immunotherapies in solid cancer
♠ 연사 : 이경미교수님 (고려대학교 의과대학)        
 ♠ 일시 : 2021년 11월 16일 17:00~18:00   
♠ 초청 : 김용성교수님(내선 2662)   

Abstract 

With the development of technologies that can transform immune cells into therapeutic modalities, immunotherapy has remarkably changed the current paradigm of cancer treatment in recent years. NK cells are components of the innate immune system that act as key regulators and exhibit a potent tumor cytolytic function. Unlike T cells, NK cells exhibit tumor cytotoxicity by recognizing non-self, without deliberate immunization or activation. Currently, researchers have developed various approaches to improve the number and anti-tumor function of NK cells. These approaches include the use of cytokines and Abs to stimulate the efficacy of NK cell function, adoptive transfer of autologous or allogeneic ex vivo expanded NK cells, establishment of homogeneous NK cell lines using the NK cells of patients with cancer or healthy donors, derivation of NK cells from induced pluripotent stem cells (iPSCs), and modification of NK cells with cutting-edge genetic engineering technologies to generate chimeric Ag receptor (CAR)- NK cells. Such NK cell-based immunotherapies are currently reported as being promising anti-tumor strategies that have shown enhanced functional specificity in several clinical trials investigating malignant tumors. Here, we summarize the recent advances in NK cell-based cancer immunotherapies that have focused on providing improved function through the use of the latest genetic engineering technologies. We also discuss the different types of NK cells developed for cancer immunotherapy and present the clinical trials being conducted to test their safety and efficacy.  

♠줌링크 

Topic: MST6016_ 분자과학기술세미나Ⅱ(O1413-1)[이경미교수님]

Time: Nov 16, 2021 05:00 PM Seoul

https://ajou-ac-kr.zoom.us/j/87481258180?pwd=ZkpOWVFGa00rUmFUeEZIVkRoSGh3Zz09

Meeting ID: 874 8125 8180

Passcode: 181316